MiNK Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Highlight Platform Expansion Across iNKT Cell Therapy Programs

About this update from Mink Therapeutics, Inc.

[{"type":"image","alt":"MiNK Therapeutics","displaySize":"","headline":null,"caption":"MiNK Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":116,"url":"https://media.zenfs.com/en/globenewswire.com/4b1b28678bcbc056b777d0ad1341f645"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/zvDa2P.MLQrfKYIZ2UPPSQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2MjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/4b1b28678bcbc056b777d0ad1341f645","width":300,"height":116}},"lazy":false},{"type":"text","content":"Recent milestones include strategic collaboration with C-Further to advance PRAME-targeted iNKT cell therapy for pediatric cancers, with meaningful downstream commercial revenue potential","length":187,"tagName":"p"},{"type":"text","content":"NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and immune disorders, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2025, before the market opens on Tuesday, March 31, 2026.","length":404,"tagName":"p"},{"type":"text","content":"The company will host a conference call and webcast at 8:30 a.m. ET that morning to review financial results and provide a corporate update on clinical progress, platform expansion, and strategic initiatives across its iNKT cell therapy portfolio.","length":247,"tagName":"p"},{"type":"text","content":"The update follows several recent corporate and development milestones, including MiNK’s newly announced collaboration with C-Further and the University of Southampton to advance a PRAME-targeted, TCR-engineered iNKT cell therapy for pediatric cancers. The collaboration brings non-dilutive funding, meaningful downstream commercial revenue potential, and further validation of MiNK’s iNKT platform in engineered cell therapy. The program expands MiNK’s presence across validated tumor antigens and underscores the broader therapeutic and strategic value of its clinically advanced, allogeneic iNKT platform.","length":608,"tagName":"p"},{"type":"text","content":"The collaboration reflects MiNK’s strategy of expanding its iNKT platform across both clinical-stage programs and engineered cell therapy approaches targeting validated tumor...

More updates from Mink Therapeutics, Inc.